Selvigaltin (GB1211), an orally readily available small molecule galectin-three inhibitor produced as a treatment method for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and security to handle regulatory specifications. Table four Statistical evaluation of dose proportionality on the pharmacokinetic parameters of https://selvigaltinoralsmallmolec57801.madmouseblog.com/19964585/not-known-details-about-selvigaltin-gb1211